The title compound, C 24 H 37 BrO 3 , is a tetracyclic diterpenoid with a beyerane skeleton, synthesized by esterification of isosteviol. It comprises a fused four-ring system A/B/C/D. Rings A and B have a chair conformation, whereas ring C is an unsymmetrical distorted chair; the remaining five-membered ring D adopts an envelope conformation. The stereochemistry of the A/B and B/C ring junctions are trans, while the C/D junction is cis.
Related literature
For the pharmacological activity of isosteviol, see: Liu et al. (2001) ; Mizushina et al. (2005) ; Wong et al. (2004) ; Xu et al. (2007) . For ring conformations, see : Cremer & Pople (1975) . For the synthesis of isosteviol derivates via esterification and bromination, see : Cai et al. (2009); Chen (2010) .
Experimental
Crystal data 
Data collection
Bruker SMART CCD area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 1999 Data collection: SMART (Bruker, 1999 ); cell refinement: SAINT (Bruker, 1999) ; data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 Isosteviol is a tetracyclic diterpenoid with a beyerane skeleton, which has good pharmacological activity against broad spectrum significant diseases including ischemia-reperfusion injury, hypertension, and cancer (Wong et al., 2004; Liu, et al., 2001; Xu, et al., 2007; Mizushina et al., 2005) . The title compound was obtained by esterification of isosteviol. The molecule structure of (I) contains a fused four-ring system A/B/C/D (Fig. 1) 
Experimental
Isosteviol was obtained by hydrolysis of stevioside with 10% sulfuric acid at 95 °C for 7 h and recrystallization from ethanol gave colorless crystals of isosteviol in 80% yield. A mixture of 1,4-dibromobutane (2.4 ml, 20 mmol), K 2 CO 3 (2.8 g, 20 mmol) and acetonitrile (20 ml) was heated to reflux. Isosteviol (3.2 g, 10 mmol) in 30 ml acetonitrile was added dropwise over 10 min, and the resulting mixture was stirred for 2 h further. The mixture was cooled to room temperature, and then distilled to one third volume under reduced pressure. The residue was poured into ice water, and the aqueous layer was extracted with CH 2 Cl 2 (3 × 50 ml). The combined CH 2 Cl 2 extracts were washed with water (1 × 50 ml) and brine (1 × 50 ml) respectively, and then dried with anhydrous Na 2 SO 4 . After the solvent was evaporated, the residue was purified by column chromatography on silica (petroleum ether/ethyl acetate = 18:1, v/v) to give the title compound (2.7 g, 60%). 
Refinement
All H atoms were placed in geometrical positions and constrained to ride on their parent atoms with C-H distances in the range 0.96-0.98 Å, and included in the final cycles of refinement using a riding model, with U iso (H) = 1.5U eq (C) for methyl H and 1.2U eq (C) for other H atoms.
supplementary materials sup-2 Figures   Fig. 1 . The molecular structure of the title compound with the atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level.
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Special details
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
Refinement. Refinement of F

